-transparent.png){kind=logo}
Four human tumour cell lines were evaluated for their ability to undergo apoptosis when subjected to cisplatin or hyperthermia treatment. In an ovarian carcinoma line (A2780s) and its derivative cisplatin resistant line (A2780cp) the variation in response was expressed for both the colony survival endpoint and the apoptosis endpoint. Apoptosis was measured by the number of floating cells, DNA agarose gels, and electron microscopy. In fact, cisplatin resistance was expressed to a higher level for apoptosis, than colony survival in the A2780cp cell line compared to the A2780s line. The melanoma cell line (Sk Mel-3) also showed induced apoptosis by cisplatin treatment while the glioma line (U87MG) showed little to no apoptosis in response to cisplatin treatment. Hyperthermia (43 degrees C for 1 hour) induced apoptosis in the human melanoma cell line but not in the glioma cell line. These data indicate that, while both cisplatin and hyperthermia can induce apoptosis in human tumour cell lines, the degree of induction is highly cell line dependent.
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
January 1999,
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group,
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
January 1991,
European journal of cancer (Oxford, England : 1990),
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
January 1990,
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group,
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
April 1988,
International journal of radiation biology and related studies in physics, chemistry, and medicine,
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
June 2002,
Biochemical pharmacology,
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
February 2019,
Scientific reports,
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
September 1990,
British journal of cancer,
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
January 2003,
Indian journal of experimental biology,
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
January 2015,
Current cancer drug targets,
G P Raaphorst, and
J Mao, and
H Yang, and
R Goel, and
B Niknafs, and
F H Shirazi, and
H M Yazdi, and
P Rippstein, and
C E Ng
February 2000,
International journal of molecular medicine,
